Literature DB >> 15021308

The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics.

Lawrence Corey1, Anna Wald, Connie L Celum, Thomas C Quinn.   

Abstract

Increasing evidence demonstrates a substantial link between the epidemics of sexually transmitted HIV-1 and herpes simplex virus (HSV)-2 infection. More than 30 epidemiologic studies have demonstrated that prevalent HSV-2 is associated with a 2- to 4-fold increased risk of HIV-1 acquisition. Per-sexual contact transmission rates among couples from Rakai, Uganda indicate that at all levels of plasma HIV-1 RNA in the source partner, HSV-2-seropositive HIV-1-susceptible persons have a 5-fold greater risk of acquiring HIV-1 compared with HSV-2-negative persons. In vitro and in vivo studies suggest that mucosal HIV-1 shedding is more frequent and in greater amounts during mucocutaneous HSV-2 replication, including subclinical mucosal reactivations. Most HIV-1-infected persons are coinfected with HSV-2, and most experience frequent subclinical and clinical reactivations of HSV-2. Subclinical HSV reactivation elevates serum HIV-1 RNA levels, and daily therapy with acyclovir appears to reduce plasma HIV-1 RNA. These data show that greater attention to the diagnosis and treatment of HSV-2 among HIV-1-infected persons is warranted, especially those who continue to be sexually active, those not on antiretroviral therapy, or those whose disease is not well suppressed by antiretrovirals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15021308     DOI: 10.1097/00126334-200404150-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  220 in total

Review 1.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  Digallate dimers of (-)-epigallocatechin gallate inactivate herpes simplex virus.

Authors:  Charles E Isaacs; Weimin Xu; George Merz; Sharon Hillier; Lisa Rohan; Guang Y Wen
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

3.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

Review 4.  Role of heparan sulfate in sexually transmitted infections.

Authors:  Vaibhav Tiwari; Erika Maus; Ira M Sigar; Kyle H Ramsey; Deepak Shukla
Journal:  Glycobiology       Date:  2012-07-06       Impact factor: 4.313

5.  Dynamics of the HIV epidemic in southern China: sexual and drug-using behaviours among female sex workers and male clients in Yunnan.

Authors:  J J Xu; M K Smith; J Chu; G W Ding; D F Chang; G B Sharp; H Z Qian; L Lu; A M Bi; N Wang
Journal:  Int J STD AIDS       Date:  2012-09       Impact factor: 1.359

6.  New insights on interactions between HIV-1 and HSV-2.

Authors:  Sinéad Delany-Moretlwe; Jairam R Lingappa; Connie Celum
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

7.  Stability of a Spodoptera frugiperda nucleopolyhedrovirus deletion recombinant during serial passage in insects.

Authors:  Oihane Simón; Trevor Williams; Robert D Possee; Miguel López-Ferber; Primitivo Caballero
Journal:  Appl Environ Microbiol       Date:  2009-12-11       Impact factor: 4.792

Review 8.  Gynecologic issues in the HIV-infected woman.

Authors:  Helen E Cejtin
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

9.  The psychosocial impact of serological herpes simplex type 2 testing in an urban HIV clinic.

Authors:  J L Meyer; R A Crosby; W L H Whittington; D Carrell; R Ashley-Morrow; A S Meier; R D Harrington; R DiClemente; A Wald
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

Review 10.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.